Abstract:Abstract Aims Lymphatics are essential for cardiac health, and insufficient lymphatic expansion (lymphangiogenesis) contributes to development of heart failure (HF) after myocardial infarction. However, the regulation and impact of lymphangiogenesis in non-ischaemic cardiomyopathy following pressure-overload remains to be determined. Here, we investigated cardiac lymphangiogenesis following transversal aortic constriction (TAC) in C57Bl/6 and Balb/c mice, and in end-stage HF patients. Methods and results Cardiac function was evaluated by echocardiography, and cardiac hypertrophy, lymphatics, inflammation, oedema, and fibrosis by immunohistochemistry, flow cytometry, microgravimetry, and gene expression analysis. Treatment with neutralizing anti-VEGFR3 antibodies was applied to inhibit cardiac lymphangiogenesis in mice. We found that VEGFR3-signalling was essential to prevent cardiac lymphatic rarefaction after TAC in C57Bl/6 mice. While anti-VEGFR3-induced lymphatic rarefaction did not significantly aggravate myocardial oedema post-TAC, cardiac immune cell levels were increased, notably myeloid cells at 3 weeks and T lymphocytes at 8 weeks. Moreover, whereas inhibition of lymphangiogenesis did not aggravate interstitial fibrosis, it increased perivascular fibrosis and accelerated development of left ventricular (LV) dilation and dysfunction. In clinical HF samples, cardiac lymphatic density tended to increase, although lymphatic sizes decreased, notably in patients with dilated cardiomyopathy. Similarly, comparing C57Bl/6 and Balb/c mice, lymphatic remodelling post-TAC was linked to LV dilation rather than to hypertrophy. The striking lymphangiogenesis in Balb/c was associated with reduced cardiac levels of macrophages, B cells, and perivascular fibrosis at 8 weeks post-TAC, as compared with C57Bl/6 mice that displayed weak lymphangiogenesis. Surprisingly, however, it did not suffice to resolve myocardial oedema, nor prevent HF development. Conclusions We demonstrate for the first time that endogenous lymphangiogenesis limits TAC-induced cardiac inflammation and perivascular fibrosis, delaying HF development in C57Bl/6 but not in Balb/c mice. While the functional impact of lymphatic remodelling remains to be determined in HF patients, our findings suggest that under settings of pressure-overload poor cardiac lymphangiogenesis may accelerate HF development.

Pharmacological Inhibition of FOXO1 Promotes Lymphatic Valve Growth in a Congenital Lymphedema Mouse Model

Foxo1 Deletion Promotes the Growth of New Lymphatic Valves

Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation.

Rictor, an mTORC2 Protein, Regulates Murine Lymphatic Valve Formation Through the AKT-FOXO1 Signaling

Endothelial Nitric Oxide Synthase Regulates Lymphatic Valve Specification by Controlling Β - Catenin Signaling During Embryogenesis

Rictor induces AKT signaling to regulate lymphatic valve formation.

A 3D biomimetic model of lymphatics reveals cell–cell junction tightening and lymphedema via a cytokine-induced ROCK2/JAM-A complex

Foxc1 and Foxc2 Deletion Causes Abnormal Lymphangiogenesis and Correlates with ERK Hyperactivation.

Temporospatial inhibition of Erk signaling is required for lymphatic valve formation

Excess Lymphangiogenesis Cooperatively Induced by Macrophages and CD4(+) T Cells Drives the Pathogenesis of Lymphedema

The mechanosensory channel PIEZO1 functions upstream of angiopoietin/TIE/FOXO1 signaling in lymphatic development

FOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure

Lentiviral overexpression of VEGFC in transplanted MSCs leads to resolution of swelling in a mouse tail lymphedema model

Lymphatic Endothelial Cells, Lymphedematous Lymphangiogenesis, and Molecular Control of Edema Formation

S1PR1 Regulates Lymphatic Valve Development And Prevents Ileitis-Independent Tertiary Lymphoid Organ Formation

Zoledronic Acid Inhibits TSC2-null Cell Tumor Growth Via RhoA/YAP Signaling Pathway in Mouse Models of Lymphangioleiomyomatosis.

Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema

[Experimental Study of Gene Therapy with Human Vascular Endothelial Growth Factor-C in Lymphedema].

Regulation and impact of cardiac lymphangiogenesis in pressure-overload-induced heart failure

Topical tissue nanotransfection of Prox1 is effective in the prophylactic management of lymphedema

[Experimental Studies of VEGF-C Gene for the Treatment of Chronic Obstructive Lymphedema in Mouse Tail Model].